Ribociclib is an oral CDK 4/6 inhibitor, approved by the US FDA for treating HR+/HER2- advanced breast cancer . CDK 4/6 inhibitors are the preferred treatment option for HR+/HER2- advanced breast cancer. The EML expert committee recognised its potential for future inclusion and recommended that MPP explore licensing opportunities to support affordable access. Ribociclib and abemaciclib are similar alternative treatment options. Ribociclib primary patents have been filed or granted in many LMICs and are expected to expire between 2027 and 2029. Secondary patents may provide exclusivity until 2031-2036 in many LMICs.

Patent & licence data in LMICs

Acronyms & abbreviations list